Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02915783
Title A Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Eisai Inc.
Indications

chromophobe renal cell carcinoma

papillary renal cell carcinoma

renal cell carcinoma

collecting duct carcinoma

Therapies

Everolimus + Lenvatinib

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
H. Lee Moffitt Cancer Center and Research Institute Tampa Florida 33612 United States Details
Rush University Medical Center Chicago Illinois 60612 United States Details
Massachusetts General Hospital Cancer Center Boston Massachusetts 02214 United States Details
Barbara Ann Karmanos Cancer Institute Detroit Michigan 48201 United States Details
Washington University Saint Louis Missouri 63110 United States Details
Weill Cornell Medical College New York New York 10065 United States Details
Texas Oncology Dallas Texas 75254 United States Details
Huntsman Cancer Institute Salt Lake City Utah 84112 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field